There is a dangerous habit in medicine and public health of forcing complex biological events into binary boxes. Either something is “normal” or it is an “injury.” Either it is “the virus” or it is “the vaccine.”
Biology does not behave that way.
When I listened to JD Vance describe what happened after his second mRNA COVID-19 dose, what struck me was not the politics but the physiology. By his own account, this was the sickest he had been in fifteen years — bed-bound for two days, heart racing, profound malaise, systemic symptoms he considered worse than any of his COVID infections.
This is not a political story. It is a biological one. The question is whether such an event should be understood as expected immune activation, or whether in some individuals it may be an early signal of a hyper-reactive immune phenotype with implications far beyond those first 48 hours.
When I approach a case like this, I start with pattern recognition. The first thing that stood out was not only the severity of the post-vaccination response but the broader immune history surrounding it. Vance described having had COVID multiple times. Repeated infections over a short interval raise an immediate question about host immune variability — whether mucosal immunity, interferon signalling, or immune memory responses differ meaningfully from the population average.
Then comes the second signal: after the second mRNA dose, the response escalates dramatically. Immunologically, this is where the system is primed. The first dose establishes recognition. The second triggers recall. Innate signalling and adaptive memory collide at the same moment. This is why second-dose systemic reactions were consistently more common in the trial data.
The regulatory framework calls this reactogenicity. Technically, that is correct. But the current framework is too coarse to capture what is actually happening in the subset of individuals with markedly exaggerated responses.
The problem with the current narrative
The dominant explanation is simple: this is a transient Grade 3 adverse effect. That classification derives from the FDA toxicity grading scale, where symptoms severe enough to prevent normal daily activity are categorised as Grade 3, even without hospitalisation or life-threatening organ injury. On paper, Vance’s experience fits — bed-bound, profound fatigue, systemic flu-like illness, marked tachycardia. The trials reported exactly this pattern after the second dose.
But I believe this explanation is incomplete.
The grading system is built around symptoms and duration. It is not designed to detect subclinical myocardial stress, endothelial activation, microvascular inflammation, or transient autonomic dysregulation that never crosses the threshold of formal myocarditis. That is a critical blind spot. A person can have biologically meaningful injury without meeting the administrative threshold of “serious adverse event.”
Medicine often confuses what is easy to classify with what is biologically true. Those are not the same thing.
Why the grey zone matters
The most important mistake we can make is to assume that because something resolves clinically within 48–72 hours, it leaves no biological footprint.
The cytokine systems involved in strong vaccine reactogenicity overlap significantly with pathways implicated in rare myocarditis and vascular inflammatory states — interferon-gamma, CXCL10, IL-6, TNF-alpha. These are essential immune mediators, but when amplified beyond the expected range, they can affect the vasculature, autonomic tone, and cardiomyocyte function.
This is why symptoms such as a racing heart should not be dismissed as anecdotal. Tachycardia in this setting may reflect systemic cytokine surge, endothelial stress, transient vascular dysregulation, or in rare cases myocardial involvement. Our systems were not built to examine the subclinical middle ground. We ask, “Was it myocarditis, yes or no?” The better question is: “What level of biological stress occurred, and what does that predict about future responses?”
FREE ACCESS - Explore the snapshot of age-stratified NHS admission analysis, including the top rising conditions in each cohort, trend trajectories, comparative controls, and detailed interpretation.
The hyper-responder phenotype
What I keep returning to is the possibility that severe acute reactogenicity is not random. It may be a marker — a marker for a hyper-reactive immune phenotype.
I do not accept the binary framing that it must be either vaccine harm or infection harm. The more biologically honest position is that a subgroup of individuals may demonstrate exaggerated inflammatory responses to repeated spike-related antigenic exposure, whether from vaccination, infection, or reinfection. That subgroup is where the real long-term risk may lie.
This is the grey zone at the centre of my broader COVID STORM framework. The issue is not what happened in the first 48 hours. The issue is what that response reveals about how that immune system may behave on future exposures — repeated infection, repeated boosters, ongoing viral circulation. If someone demonstrates a clear hyper-inflammatory pattern, that should place them into a cohort requiring more careful long-term follow-up. Not because pathology is inevitable, but because uncertainty in medicine is where monitoring should begin, not where curiosity ends.
The cardiovascular signal we cannot ignore
The broader population data continue to show cardiovascular trajectories moving in concerning directions — myocarditis, pericarditis, hypertensive disease, heart failure, pulmonary embolic phenomena. These are rising signals that deserve mechanistic explanation.
The intellectually lazy answer is to assign all of it to one source. I do not think either extreme — “the virus caused it” or “the vaccine caused it” — adequately explains what we are seeing. The more plausible explanation is interaction: a susceptible host, a primed immune system, repeated antigenic exposures, persistent viral circulation, and ongoing inflammatory triggers. That interaction model fits the data better than ideological absolutes.
What must happen next
The current framework is too blunt. A severe post-vaccine response should not be minimised simply because it resolved. It should be used as a clinical signal. People with prior Grade 3-type responses, especially with cardiac symptoms, should be followed longitudinally — cardiac biomarkers, ECG monitoring, inflammatory markers, long-term symptom tracking. This is precision medicine. Not panic, not denial, not politics.
What concerns me most is the rush to move on. Biology does not move on because the public narrative does. If a subset of individuals enter repeated hyper-inflammatory states after exposure, whether through infection or vaccination, ignoring that cohort will not make the signal disappear. It will delay recognition until it manifests as chronic disease.
The deeper lesson
The Vance case is not about one politician. It is a high-profile example of a broader phenomenon many people experienced but felt unable to discuss in biologically precise terms. The real issue is not whether severe post-dose illness was permitted to be talked about. The real issue is whether we have been asking the right scientific questions.
The mechanism that continues to concern me is this: a subset of people appear to declare themselves early as immune hyper-responders. Those individuals may represent the very cohort most at risk for long-term vascular, autonomic, and inflammatory sequelae in the post-pandemic era.
That is where the science must go next. Not backward into politics. Forward into physiology.
Vejon COVID-19 Review is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
